FDA Revises Its Drug-Delivery Device Test Guidance

FDA has rewritten, and renamed, its guidance on how sponsors of drug-delivery devices should test and control performance — more than two years after the original draft drew industry pushback over unclear terminology and open-ended testing burdens. The revised draft, published October 30, 2026, swaps "essential drug delivery output" for "essential drug delivery performance characteristic," and ties the rewrite to FDA's revised Quality Management System Regulation.

What the 2024 draft asked for, and why it changed

FDA's original June 2024 draft introduced "essential drug delivery outputs" (EDDOs) to replace an older, informally used term, "essential performance requirements," that the agency and sponsors had relied on in review correspondence without a fixed definition. The draft directed sponsors to identify the device design outputs necessary to ensure a combination product actually delivers its intended drug dose to the intended site, and to submit supporting testing data in investigational, marketing and post-market change applications. Industry stakeholders, responding during the comment period that closed September 30, 2024, asked FDA to clarify key terminology and avoid open-ended new testing burdens, and some requested an implementation period of a year or more once any guidance was finalized. The head of FDA's Office of Combination Products later acknowledged those concerns publicly at an industry summit. The October 30 revision is FDA's response: a new term, a narrower and more structured set of worked examples, and an explicit tie to the revised Quality Management System Regulation that took effect for combination products in the interim.

What's actually in the revision

The renamed "essential drug delivery performance characteristics" (EDDCs) serve the same underlying purpose as the 2024 draft's EDDOs: identifying and verifying the device-side design elements — dose accuracy, delivery rate, actuation force, needle insertion depth, and similar outputs depending on device type — that a sponsor must demonstrate are met, including after preconditioning for storage and shipping and across the product's shelf life. What changes with the revision, per trade-press coverage, is structural: four appendices now walk through specific device categories rather than leaving sponsors to generalize from abstract principles, with prefilled syringes and autoinjectors — the two most common drug-delivery device types in current combination-product submissions — each getting dedicated treatment, and a worked control-strategy example for an autoinjector with an extended needle length in Appendix D.

Why RA/QA teams should track this

• Combination-product sponsors already working from the 2024 draft: the terminology change from EDDO to EDDC is not cosmetic for submission documents, design history files or internal SOPs that adopted the 2024 language — budget time to reconcile naming before your next investigational or marketing submission.
• Prefilled syringe and autoinjector programs specifically: Appendices A, B and D are the most directly actionable sections for these device types; review them against your current design-verification protocol rather than relying on a summary of the change.
• Quality teams implementing the revised QMSR: this guidance is explicitly positioned as aligned with 21 CFR Part 820 as revised — a useful cross-reference if your QMSR transition work has not yet addressed drug-delivery device performance testing specifically.

What is not yet settled

This is a draft, not a final guidance, and FDA's own framing says it reflects current thinking rather than binding requirements. Comments are open through January 28, 2027, and FDA can revise the EDDC framework, the appendices, or the terminology again before finalizing. Regulatory News has not independently reviewed the full text of the revised guidance beyond the summaries and the Federal Register notice cited below; sponsors relying on specific appendix content for a live submission should consult the primary document directly rather than this summary.

Frequently asked questions

What did FDA publish on 30 October 2026?

A revised draft guidance replacing the July 2024 draft on drug-delivery device performance, renaming its central concept from “essential drug delivery output” to “essential drug delivery performance characteristic.” Federal Register document 2026-22203, docket FDA-2024-D-2560.

What actually changed from the 2024 draft?

The core terminology (EDDO to EDDC), updated testing and control recommendations, and alignment with the revised Quality Management System Regulation at 21 CFR Part 820.

What products does this cover?

Drug-delivery devices and combination products — prefilled syringes, autoinjectors, infusion products, nasal sprays, inhalers, nebulizers and vaginal delivery systems — with four appendices covering specific device types and worked examples.

How do I comment, and what's the deadline?

Submit comments to docket FDA-2024-D-2560 via Regulations.gov by 28 January 2027.